Board of Directors
Matthew Emmens (59)
Chairman
Mr Emmens was appointed Chairman on June 18, 2008 and has been a member of the Board since March 12, 2003. He is also a member of the Nomination Committee. He was the Company’s Chief Executive Officer from March 2003 to June 2008. Mr Emmens brings to the Board, among other things, his operational knowledge of Shire and his wealth of international sales, marketing, integration and operational experience in the pharmaceutical sector. Mr Emmens also serves as Chairman, President and Chief Executive Officer of Vertex Pharmaceuticals Inc. He is a former board member of Incyte Corporation. Mr Emmens began his career in international pharmaceuticals with Merck & Co, Inc. in 1974, where he held a wide range of sales, marketing and administrative positions. In 1992, he helped to establish Astra Merck, a joint venture between Merck and Astra AB of Sweden, becoming President and Chief Executive Officer. In 1999, he joined Merck KGaA and established EMD Pharmaceuticals, the company’s US prescription pharmaceutical business. He was later based in Darmstadt, Germany as President of Merck KGaA’s global prescription pharmaceutical business and was a board member. Mr Emmens holds a degree in Business Management from Fairleigh Dickinson University.
Angus Russell (55)
Chief Executive Officer
Mr Russell was appointed Chief Executive Officer on June 18, 2008 and has been a member of the Board since December 13, 1999. He was the Company’s Chief Financial Officer from December 1999 to June 2008. He is also Chairman of the Company’s Leadership Team. Mr Russell brings to his position, among other things, his operational knowledge of Shire and his extensive finance, risk management, strategic and operational experience in the pharmaceutical sector. Mr Russell is a former Non-Executive Director of the City of London Investment Trust plc. Between 1980 and 1999, he held a number of positions of increasing responsibility at ICI, Zeneca and AstraZeneca PLC, including Vice President, Corporate Finance at AstraZeneca and Group Treasurer at Zeneca. Mr Russell is a Chartered Accountant and is a Fellow of the Association of Corporate Treasurers.
Graham Hetherington (52)
Chief Financial Officer
Mr Hetherington has been the Chief Financial Officer and a member of the Board since July 1, 2008. He is also a member of the Leadership Team. Mr Hetherington brings to his position, among other things, a broad range of international finance management and planning, audit, risk management and M&A experience. Mr Hetherington most recently held positions as the Chief Financial Officer of Bacardi in 2007 and Chief Financial Officer of Allied Domecq plc from 1999 to 2005. Mr Hetherington is a Fellow of the Chartered Institute of Management Accountants.
David Kappler (63)
Deputy Chairman and Senior Independent Non-Executive Director
Mr Kappler has been a member of the Board since April 5, 2004. He was appointed Senior Independent Non-Executive Director in July 2007 and Deputy Chairman in June 2008. He is Chairman of the Nomination Committee and of the Audit, Compliance & Risk Committee. Mr Kappler brings to the Board, among other things, his extensive knowledge and experience in financial reporting, risk management and internal financial controls. Mr Kappler also serves as a Non-Executive Director of InterContinental Hotels Group plc. He was Non-Executive Chairman of Premier Foods plc until September 2010 and was a Non-Executive Director of Camelot Group plc from 1996 to 2002 and of HMV Group plc from 2002 to 2006. Mr Kappler retired from Cadbury Schweppes plc in April 2004 after serving as Chief Financial Officer since 1995. He worked for the Cadbury Schweppes group between 1965 and 1984 and rejoined the company in 1989 following its acquisition of the Trebor Group, where he was Financial Director. Mr Kappler is a Fellow of the Chartered Institute of Management Accountants.
Dr Jeffrey Leiden (55)
Vice Chairman and Non-Executive Director
Dr Leiden has been a member of the Board since January 1, 2007, and Vice Chairman since April 2009. He is a member of the Remuneration Committee and of the Nomination Committee and Chairman of the Science & Technology Committee. Dr Leiden brings to the Board, among other things, his extensive operational experience in pharmaceutical companies and his operational and scientific experience in clinical research, development and registration. Dr Leiden is also a Managing Director at Clarus Ventures LLC, Chairman of the Board of Directors of TyRx Pharma, Inc., Lycera Corporation and Variation Biotechnologies Inc., and a member of the Board of Directors of Biolex Therapeutics Inc., Catabasis Pharmaceuticals Inc. and Vertex Pharmaceuticals Inc. Dr Leiden served as President and Chief Operating Officer, Pharmaceutical Products Group and Chief Scientific Officer at Abbott Laboratories from 2001 to 2006; during this time he was also a member of the Boards of Directors of Abbott and TAP Pharmaceutical Products, Inc. Prior to joining Abbott, Dr Leiden served as the Elkan R. Blout Professor of Biological Sciences, Harvard School of Public Health and Professor of Medicine, Harvard Medical School. Previously, he was the Frederick H. Rawson Professor of Medicine and Pathology and Chief of the Section of Cardiology at the University of Chicago. Dr Leiden was a founder of Cardiogene, Inc., a biotechnology company specializing in cardiovascular gene therapy. Dr Leiden earned a bachelor’s degree in biological sciences, a doctorate in virology and a medical degree, all from the University of Chicago. He is a Fellow of the American Academy of Arts and Sciences and an elected member of the Institute of Medicine of the National Academy of Sciences.
William Burns (63)
Non-Executive Director
Mr Burns was appointed to the Board on March 15, 2010 and is a member of the Remuneration Committee. Mr Burns brings to the Board, among other things, extensive experience in international sales, marketing, integration and operational experience in the pharmaceutical sector. He also holds directorships at Crucell N.V., Roche Holdings Ltd, Chugai Pharmaceuticals and Genentech Inc. Mr Burns worked for many years for Roche; most recently as CEO of their Pharmaceuticals Division and as a member of the Roche Group Corporate Executive Committee. Among his many achievements during his time with Roche, he had significant involvement in the acquisition and privatization of Genentech, he led the integration of Boehringer Mannheim Therapeutics and he played a lead role in the negotiations resulting in Roche becoming a majority owner of Chugai in Japan.
Dr David Ginsburg (58)
Non-Executive Director
Dr Ginsburg, MD was appointed to the Board on June 16, 2010 and is a member of the Science & Technology Committee. Dr Ginsburg is currently James V. Neel Distinguished University Professor of Internal Medicine Human Genetics, and Pediatrics at the University of Michigan and a Howard Hughes Medical Institute Investigator. Dr Ginsburg brings much experience to the Board, including his clinical medical background in Internal Medicine, Hematology-Oncology, and Medical Genetics, as well as his extensive basic biomedical laboratory research expertise. He obtained his BA at Yale University, MD at Duke University and completed his medical and research training at Harvard Medical School, before joining the faculty at the University of Michigan. Dr Ginsburg is the recipient of numerous honors and awards, including election to membership in the National Academy of Sciences, the Institute of Medicine and the American Academy of Arts and Sciences.
Patrick Langlois (65)
Non-Executive Director
Mr Langlois has been a member of the Board since November 11, 2005. He is also a member of the Audit, Compliance & Risk Committee and of the Remuneration Committee. Mr Langlois brings to the Board, among other things, his extensive experience in financial reporting, audit and risk management. Mr Langlois is a Non-Executive Director of Scynexis Inc., Nanobiotix S.A., Exonhit S.A. and Newron Spa. Mr Langlois previously served as Vice Chairman of the Management Board of Aventis S.A., having been Group Executive Vice President and Chief Financial Officer for several years. He also spent many years in senior financial roles with the Rhône-Poulenc Group, including three years as a member of the Executive Committee and Chief Financial Officer. Mr Langlois holds a PhD in Economics and a diploma in banking studies.
Anne Minto OBE (57)
Non-Executive Director
Ms Minto was appointed to the Board on June 16, 2010 and is Chair of the Remuneration Committee. Ms Minto is Group Director Human Resources at Centrica plc and sits on the Centrica Executive Committee. She was chair of the three Centrica Pension Scheme boards for eight years until end of December 2010. She brings considerable experience to the Board including, her extensive legal, commercial and remuneration experience. Following her law degree at Aberdeen University and a post graduate diploma in Human Resources she qualified as a lawyer and has an extensive business career that includes senior management roles at Shell UK, the position of deputy director-general of the Engineering Employers’ Federation and the position of Group Director Human Resources at Smiths Group plc. She has also been a Non-Executive director on the boards of Northumbrian Water plc and SITA UK. Ms Minto is a Fellow of the Chartered Institute of Personnel & Development, the Royal Society of Arts and the London City and Guilds and a Member of Law Society of Scotland.
David Stout (56)
Non-Executive Director
Mr Stout was appointed to the Board on October 31, 2009 and is a member of the Audit, Compliance & Risk Committee. Mr Stout brings to the Board, among other things, extensive international sales, marketing, operational and supply chain experience gained in the pharmaceutical sector. Mr Stout also holds directorships at Allos Therapeutics, Inc., Jabil Circuit, Inc. and Airgas Inc. Most recently he was President, Pharmaceutical Operations at GSK. In this position he had responsibility for pharmaceutical operations in the United States, Europe, Japan and all other International Markets. Mr Stout was also responsible for global manufacturing and global Biologics (vaccines) at GSK. Prior to that, he was President of GSK’s US Pharmaceuticals Business and before that SmithKline Beecham’s North American Pharmaceuticals Business. Before joining SmithKline Beecham, Mr Stout worked for many years at Schering-Plough.
Former Non-Executive Directors
Kathleen Nealon (57)
Non-Executive Director
Ms Nealon was a member of the Board from July 27, 2006 to July 26, 2010. When Ms Nealon stepped down from the Board, she also stepped down from her role as Chair of the Remuneration Committee and as a member of the Audit, Compliance & Risk Committee. Ms Nealon brought to the Board, among other things, her extensive global legal, compliance and risk management experience gained through roles held in multinational companies. Ms Nealon is a Non-Executive Director of Cable & Wireless Communications Plc and a former Non-Executive Director of HBOS plc. She is also a Senior Associate at the Judge Business School at Cambridge University. Ms Nealon was previously Group Head of Legal & Compliance at Standard Chartered plc until 2004. She is a US qualified lawyer and spent several years in her early career practising law in New York.
Dr Barry Price (67)
Non-Executive Director
Dr Price was a member of the Company’s Board from January 16, 1996 until his retirement from the Board on January 24, 2010. He was a member of the Company’s Nomination Committee and Science & Technology Committee until October 2009 and January 2010 respectively. Dr Price brought to the Board, among other things, his wealth of experience in the operational and scientific aspects of clinical research and development. He serves as Chairman of Antisoma plc and Summit Corporation plc. In recent years he has held directorships at Chiroscience plc, Celltech Group plc, Pharmagene plc and BioWisdom Limited. Dr Price worked for GSK for 28 years, where he held positions of increasing responsibility with that company’s research group.